Vanda Pharmaceuticals company info

What does Vanda Pharmaceuticals do?
Vanda Pharmaceuticals (NASDAQ:VNDA) is a biopharmaceutical company focused on the development and commercialization of innovative therapies to address unmet medical needs. The company’s portfolio includes products in the areas of psychiatry, neurology, and dermatology, among others. Vanda is committed to improving patient outcomes through research and development of novel treatments. Key projects include treatments for conditions such as schizophrenia, non-24-hour sleep-wake disorder, and atopic dermatitis. Vanda’s objectives consist of advancing its clinical development programs, expanding its product portfolio through strategic partnerships and acquisitions, and delivering sustainable growth. The company strives to make a meaningful difference in patients' lives through its pioneering work in the healthcare sector.
Vanda Pharmaceuticals company media
Company Snapshot

Is Vanda Pharmaceuticals a public or private company?

key
Ownership
Public

How many people does Vanda Pharmaceuticals employ?

people
Employees
273

What sector is Vanda Pharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for Vanda Pharmaceuticals?

location pin
Head Office
Washington, D.C., United States

What year was Vanda Pharmaceuticals founded?

founded flag
Year Founded
2002
What does Vanda Pharmaceuticals specialise in?
/Pharmaceutical Products /Neurological Therapies /Rare Diseases /Drug Development /Clinical Trials /Behavioral Disorders

What are the products and/or services of Vanda Pharmaceuticals?

Overview of Vanda Pharmaceuticals offerings
HETLIOZ (tasimelteon) - Treatment for Non-24-Hour Sleep-Wake Disorder (Non-24) and Smith-Magenis Syndrome-related sleep disorders.
Fanapt (iloperidone) - An antipsychotic medication for the treatment of schizophrenia.
Tradipitant - An investigational new drug potentially for the treatment of gastroparesis, atopic dermatitis, and motion sickness.
VLY-686 (Tradipitant) - A neurokinin-1 receptor antagonist, in development stages for various conditions including chronic pruritus and cough.
HETLIOZ LQ - A liquid formulation of tasimelteon designed for individuals who have difficulty swallowing capsules, targeting Non-24-Hour Sleep-Wake Disorder.

Who is in the executive team of Vanda Pharmaceuticals?

Vanda Pharmaceuticals leadership team
  • Dr. Mihael H. Polymeropoulos M.D.
    Dr. Mihael H. Polymeropoulos M.D.
    Founder, President, CEO & Chairman of The Board
  • Mr. Kevin Patrick Moran
    Mr. Kevin Patrick Moran
    Senior VP, CFO & Treasurer
  • Mr. Timothy  Williams
    Mr. Timothy Williams
    Senior VP, General Counsel & Secretary
  • Mr. Joakim  Wijkstrom
    Mr. Joakim Wijkstrom
    Senior VP & Chief Marketing Officer
  • Mr. Gunther  Birznieks
    Mr. Gunther Birznieks
    Senior Vice President of Business Development
  • Mr. Scott L. Howell
    Mr. Scott L. Howell
    Chief People Officer
  • Ms. Elizabeth  Van Every
    Ms. Elizabeth Van Every
    Head of Corporate Affairs